Abstracts tagged "Prognostic factors and rheumatoid arthritis (RA)"

Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Jorge Rojas-Serrano¹, Denisse Herrera-Bringas², Renzo Perez-Dorame³, Mayra Mejia² and Heidegger Mateos-Toledo⁴, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Interstitial Lung Diseases Unit, Insituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico
Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…
Abstract Number: 2605 • 2015 ACR/ARHP Annual Meeting
14-3-3η Positive Status and Higher Titres Are Associated with More Severe RA
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Serum 14-3-3η is an RA diagnostic marker that is associated with radiographic progression risk. In vitro studies describe 14-3-3η's potent, dose-dependent up-regulation of factors…
Abstract Number: 2625 • 2015 ACR/ARHP Annual Meeting
SDAI 50 Is More Stringent Than the EULAR Response Measure and a Better Predictor of Low Disease State/Remission in Early Rheumatoid Arthritis: Results from an Early Arthritis Cohort
Mohammed Omair¹, Edward C. Keystone², VP Bykerk³, Boulos Haraoui⁴, Gilles Boire⁵, J Carter Thorne³, Janet E. Pope⁶, Daming Lin⁷, Carol Hitchon⁸ and Pooneh S.Akhavan⁹, ¹Rheumatology, Mount Sinai hospital, Toronto, ON, Canada, ²University of Toronto/Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶St. Joseph's Health Care, London, ON, Canada, ⁷mount Sinai Hospital, Toronto, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹mount sinai hospital, Toronto, ON, Canada
Background/Purpose: To compare the sensitivity of the EULAR and SDAI50 response measures (RMs) and their impact on future response to treatment in patients with early…
Abstract Number: 3253 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Antibodies to Cyclic Citrullinated Peptide in Two Prospective Early Rheumatoid Arthritis Cohorts 10 Years Apart
Alf Kastbom¹, Michael Ziegelasch¹, Ingrid Thyberg¹, Birgir Arge², Klara Martinsson¹, Olle Svernell³, Åsa Häggström⁴, Per Salomonsson⁵, Britt-Marie Nyhäll-Wåhlin⁶, Sören Transö⁷, Claudia Jacobs⁸ and Thomas Skogh¹, ¹IKE/Rheumatology, Linköping University, Linköping, Sweden, ²Rheumatology clinic, Eskilstuna Hospital, Eskilstuna, Sweden, ³Rheumatology Dpt, Västervik Hospital, Västervik, Sweden, ⁴Rheumatology clinic, Kalmar Hospital, Kalmar, Sweden, ⁵Rheumatology Clinic, Örebro University Hospital, Örebro, Sweden, ⁶Department of Rheumatology, Falun Hospital, Falun, Sweden, ⁷Rheumatology Clinic, Ryhov Hospital, Jönköping, Sweden, ⁸Rheumatology Dept, Oskarshamn Hospital, Oskarshamn, Sweden
Background/Purpose: Antibodies to cyclic citrullinated peptides (anti-CCP) associate with a more severe rheumatoid arthritis (RA) disease course, and therefore have influence on therapeutic decisions. By…
Abstract Number: 3254 • 2015 ACR/ARHP Annual Meeting
A Clinical Risk Score to Predict Functional Disability at 1 Year in an Early Rheumatoid Arthritis Inception Cohort
Caroline Kronisch^1,2, David Mclernon³, James Dale⁴, Caron Paterson⁴, Stuart H. Ralston⁵, David M. Reid⁶, Ann Tierney⁴, John Harvie⁷, Neil McKay⁸, Hilary E. Wilson⁹, Robin Munro¹⁰, Sarah Saunders¹¹, Ruth Richmond¹², Derek Baxter¹³, Mike McMahon¹⁴, Vinod Kumar¹⁵, John McLaren¹⁶, Stefan Siebert⁴, Iain B. McInnes¹⁷, Duncan Porter⁴, Gary J. Macfarlane² and Neil Basu², ¹Department of Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ²Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ³Musculoskeletal Research Collaboration (Medical Statistics Team), University of Aberdeen, Aberdeen, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ⁶Musculoskeletal Research Collaboration (Medicine & Therapeutics), University of Aberdeen, Aberdeen, United Kingdom, ⁷Department of Rheumatology, Raigmore Hospital, Inverness, United Kingdom, ⁸Department of Rheumatology, Western General Hospital, Edinburgh, United Kingdom, ⁹Department of Rheumatology, Stobhill General Hospital, Glasgow, United Kingdom, ¹⁰Department of Rheumatology, Wishaw General Hospital, Lanarkshire, United Kingdom, ¹¹Centre of Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom, ¹²Department of Rheumatology, Borders General Hospital, Melrose, United Kingdom, ¹³Department of Rheumatology, University Hospital Ayr, Ayr, United Kingdom, ¹⁴Department of Rheumatology, Dumfries & Galloway Royal Infirmary, Dumfries, United Kingdom, ¹⁵Department of Rheumatology, Ninewells Hospital, Dundee, United Kingdom, ¹⁶Department of Rheumatology, Whyteman Brae Hospital, Fife, United Kingdom, ¹⁷Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: When diagnosed with rheumatoid arthritis (RA), patients are especially concerned by the prospect of disability. Predictors of future disability may inform early decision making.…
Abstract Number: 1435 • 2014 ACR/ARHP Annual Meeting
Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan.
Yoichiro Akiyama¹, Takeo Sato¹, Takamasa Murosaki¹, Katsuya Nagatani¹ and Seiji Minota², ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi-Ken, Japan
[Background/Purpose ] Infliximab was introduced in 2002 as the first biological DMARD (bDMARD) in Japan. Currently, 5 TNF inhibitors, tocilizumab, and abatacept are available. Tacrolimus…
Abstract Number: 454 • 2014 ACR/ARHP Annual Meeting
The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis
Jing Shi, H.W. van Steenbergen, J. a. B. van Nies, E.W.Nivine Levarht, Annette H. M. van der Helm- van Mil, Tom W. J. Huizinga, René E.M. Toes and Leendert A. Trouw, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Anti-carbamylated protein (anti-CarP) antibodies have been described in rheumatoid arthritis (RA) and arthralgia patients [1;2] and occur in subsets of the anti-CCP2 positive and…
Abstract Number: 432 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression
Yashaar Chaichian¹, Imre Noth¹, Mary Strek¹, Tammy O. Utset² and Rekha Vij¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose Rheumatoid arthritis (RA) is the most common systemic connective tissue disease in the U.S. Interstitial lung disease (ILD) is a frequent extra-articular manifestation of…
Abstract Number: 359 • 2014 ACR/ARHP Annual Meeting
14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
Anthony Marotta¹, Samina Turk², Mairead Murphy³, Walter P. Maksymowych⁴ and Dirkjan van Schaardenburg⁵, ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, there are auto-antibodies (AAb) to…
Abstract Number: L13 • 2013 ACR/ARHP Annual Meeting
Serum 14-3-3η Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients
D. van Schaardenburg¹, Marian van Beers-Tas², Karin Britsemmer², Mairead Murphy³, Walter P. Maksymowych⁴, Maarten Boers⁵ and Anthony Marotta⁶, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁶Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The focus of RA management is increasingly towards early detection and treatment. While newly-diagnosed patients will benefit from treatment decisions based on more robust…
Abstract Number: 2292 • 2013 ACR/ARHP Annual Meeting
Factors Affecting The Discrepancy Between Physician and Patient Global Assessment Of Disease Activity In Early and Established Rheumatoid Arthritis Patients- Results From The Ontario Best Practices Initiative
Pooneh Akhavan¹, Binu Jacob², Edward C. Keystone^3,4, Xiuying Li⁵, J. Carter Thorne⁶ and Claire Bombardier⁷, ¹Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁴University of Toronto/Mount Sinai Hospital, Toronto, ON, Canada, ⁵Clinical Decision Making and Health Care, University Health Network, Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Discrepancy between patient (PGA) and physician (MDGA) global assessments in Rheumatoid Arthritis (RA) can adversely affect therapeutic decisions. The pattern of PGA and MDGA,…
Abstract Number: 2238 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort
Bernard Combe¹, Isabelle Logeart², M. Belkacemi³, S Dadoun⁴, Jean-Pierre Daurès⁵ and Maxime Dougados⁶, ¹Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ²Pfizer, Paris, France, ³CHRU Montpellier, Montpellier, France, ⁴Paris-Pitié Salpêtrière University Hospital, Paris, France, ⁵Service BESPIM, CHU, Nimes, France, ⁶Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Treat to Target and EULAR recommendations highlighted the need for achieving and maintaining remission in patients with early RA. We investigated if early…
Abstract Number: 1321 • 2013 ACR/ARHP Annual Meeting
Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis
Rosario Garcia-Vicuña¹, Ana M. Ortiz², Iria Valino-Seoane³, Amalia Lamana¹, Javier Leceta³, Yasmina Juarranz³, Isidoro González-Alvaro², Rosa P Gomariz³ and Carmen Martinez-Mora⁴, ¹Rheumatology, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, ²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ³Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, ⁴Cellular Biology, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The current shift to earlier treatment of Rheumatoid Arthritis (RA) has a major unmet need in the availability of biomarkers to identify patients requiring more…
Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting
Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Lillian J. Barra¹, Janet E. Pope², Boulos Haraoui³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Edward C. Keystone^6,7, Diane Tin⁸, Gilles Boire⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
Abstract Number: 953 • 2013 ACR/ARHP Annual Meeting
Baseline Serum Interleukin-34 Levels Predict Radiographic Progression In Rheumatoid Arthritis Patients
Sung Hae Chang^1,2, Byoung Youg Choi³, Hyon Joung Cho⁴, Hye Jin Oh⁵, Eun Ha Kang³, Yeong Wook Song^2,6 and Yun Jong Lee^2,7, ¹Internal Medicine Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ³Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁵Internal Medicine, Rheumatology, Seoul National University Hospital, Seoul, South Korea, ⁶Internal Medicine,Rheumatology, Seoul National University Hospital, Seoul, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: Interleukin-34 (IL-34), a novel cytokine playing a critical role in osteoclastogenesis, recently was reported that its expression increases in the synovial tissue and sera…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].